Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Update on the Use of L-Asparaginase in Infants and Adolescent Patients with Acute Lymphoblastic Leukemia

1 Jan 2014

Abstract excerpt

Great improvements have been made in acute lymphoblastic leukemia (ALL) treatment in the past decades, especially due to the use of l-asparaginase (l-ASP). Despite the significant success rate, several side effects mainly caused by toxicity, asparaginase silent inactivation, and cellular resistance, encourage an open debate regarding the optimal dosage and formulation of l-ASP. Alternative sources of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acute Lymphoblastic Leukemia research
Share to Adolescent and Pediatric Healthcare
Share to Childhood Cancer Survivors' Quality of Life

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 25210485
DOI: 10.4137/cmo.s10242

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Update on the Use of L-Asparaginase in Infants and Adolescent Patients with Acute Lymphoblastic LeukemiaPMID 25210485Read ↗

Possible mechanism of metabolic and drug resistance with L-asparaginase therapy in childhood leukaemiaSemantic proximity Read ↗

Asparagine: A Metabolite to Be Targeted in CancersSemantic proximity Read ↗

Novel Genetic Risk Factor Identified for L-Asparaginase-Induced Pancreatitis in Pediatric Patients With Cancer.Semantic proximity Read ↗

Identification of a cytogenetic and molecular subgroup of acute myeloid leukemias showing sensitivity to L-AsparaginaseSemantic proximity Read ↗

Asparagine Synthetase ChemotherapySemantic proximity Read ↗

Review of pharmacogenetics studies of L-asparaginase hypersensitivity in acute lymphoblastic leukemia points to variants in the GRIA1 gene.Semantic proximity Read ↗

Red blood cell-encapsulated L-asparaginase: potential therapy of patients with asparagine synthetase deficient acute myeloid leukemia.Semantic proximity Read ↗

Structural and biochemical properties of L‐asparaginaseSemantic proximity Read ↗

Biogeneric native and polyethylene glycol-conjugated <i>E. coli</i> asparaginases for treating children with acute lymphoblastic leukaemiaSemantic proximity Read ↗

Genome-wide loss-of-function genetic screening identifies opioid receptor μ1 as a key regulator of L-asparaginase resistance in pediatric acute lymphoblastic leukemiaSemantic proximity Read ↗

The characteristics and risk factors of asparaginase-associated pancreatitis in pediatric acute lymphoblastic leukemiaSemantic proximity Read ↗

Metabolic Profile Of Leukemia Cells Influences Treatment Efficacy Of L‑AsparaginaseSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.